GILD Gilead Sciences

8-K Current Report

Filed: February 23, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Gilead Sciences (GILD) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 7.01: Regulation FD Disclosure
Item 1.01: Entry into a Material Definitive Agreement

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Gilead acquiring Arcellx at $115.00/share cash + $5.00 CVR per share, implying up to $120.00 total consideration per Arcellx share
• CVR milestone: $5.00 payment contingent on anito-cel cumulative global sales exceeding $6B by December 31, 2029 — high bar, meaningful execution risk

+3 more insights

Item 7.01 · Regulation FD Disclosure

• Gilead pursuing full acquisition of Arcellx via tender offer — deal not yet commenced, SEC filings pending
• Key asset: anito-cel (CAR-T therapy), with active BLA under FDA review and a PDUFA date already set

+3 more insights

Get deeper insights on Gilead Sciences

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.